ESMA — Endometriosis Silencing Molecular Approach
Reimagining endometriosis treatment at the source.
Esma Bio is a preclinical-stage company developing a targeted molecular therapeutic for endometriosis — designed to act on the disease at the level of the lesion, with the goal of avoiding the systemic endocrine suppression, bone loss, and duration limits of current care.
190M
women affected globally
7–10 yrs
average diagnostic delay
Recurrence
after treatment is common
The Unmet Need
Endometriosis has been stuck in a hormonal paradigm for decades.
Affecting nearly 190 million women globally, endometriosis remains one of the most underserved diseases in modern medicine. The standard of care has not meaningfully evolved in a generation.
190M
women affected globally
7–10 yrs
average diagnostic delay
Recurrence
after treatment is common
Disease Burden
A debilitating disease, often invisible
Endometriosis causes chronic pelvic pain, infertility, and systemic inflammation. Patients endure years of misdiagnosis before reaching a specialist, and many lose career years and quality of life to a disease that is still poorly understood and undertreated.
Treatment Limitations
Hormones and surgery — neither is a cure
Existing therapies suppress estrogen system-wide, carrying bone-density and tolerability penalties that limit their duration of use. Surgery is invasive and the disease frequently recurs. No therapy on the market addresses the underlying biology of the lesion itself.
The Esma Bio Approach
Beyond hormones and surgery.
Esma Bio is taking a targeted, lesion-selective approach designed to act locally within endometriotic lesions while sparing normal systemic endocrine function — an alternative to the system-wide hormonal suppression and surgery that define current care. The program is at the preclinical research stage.
Development Roadmap
From candidate to clinic.
Esma Bio is at the preclinical stage, with in vitro validation underway.
Detailed timelines and regulatory strategy are shared with qualified partners under CDA.